As of May 29
| -0.10 / -4.90%|
The 1 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.60, with a high estimate of 2.60 and a low estimate of 2.60. The median estimate represents a +34.02% increase from the last price of 1.94.
The current consensus among 1 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.